Early PSA decrease is an independent predictive factor of clinical failure specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 903-904

  Heyns, C F ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ANTIGEN DETECTION; BRACHYTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; TREATMENT FAILURE; TUMOR CELL DESTRUCTION;

EID: 77951962424     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp554     Document Type: Letter

References (1)

1. de Crevoisier R, Slimane K, Messai T et al. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. Ann Oncol 2010; 21: 808-814.